Sangamo Therapeutics Files Chapter 11; Submits June 2026 Monthly Report

What Happened

• Sangamo Therapeutics, Inc. announced it commenced a voluntary Chapter 11 case in the U.S. Bankruptcy Court for the District of Delaware on June 23, 2026 (Case No. 26-10989, styled In re Sangamo Therapeutics, Inc.).
• On August 6, 2026 the company filed its monthly operating report (MOR) for the period June 1–June 30, 2026 with the Bankruptcy Court; this filing was disclosed under Item 7.01 (Regulation FD Disclosure) of the Form 8-K.

Key Details

• Chapter 11 petition filed: June 23, 2026 (voluntary petition under the Bankruptcy Code).
• Bankruptcy Court: United States Bankruptcy Court for the District of Delaware.
• Case number: 26-10989 (styled In re Sangamo Therapeutics, Inc.).
• Monthly Operating Report (MOR) for June 1–30, 2026 was filed on August 6, 2026 and is included as Exhibit 99.1 to the 8-K.

Why It Matters

• The company is actively in a Chapter 11 bankruptcy case, which is a formal legal process that oversees restructuring or other court-supervised resolutions.
• The MOR provides updated operational and financial information for June 2026 and is a primary source for investors and creditors to track the company’s short-term results and cash usage.
• Investors should review the MOR and bankruptcy court filings for details on operations, cash position, creditor claims, and potential next steps in the Chapter 11 process.